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Abstract
Endothelial dysfunction contributes to the development of coronary heart disease (CHD). Soluble
epoxide hydrolase metabolizes epoxyeicosatrienoic acids in the vasculature and regulates endothelial
function. We sought to determine whether genetic variation in soluble epoxide hydrolase (EPHX2)
was associated with the risk of CHD. We genotyped 2065 Atherosclerosis Risk in Communities study
participants (1085 incident CHD cases, 980 non-cases) for 10 previously identified polymorphisms
in EPHX2. Using a case–cohort design, associations between incident CHD risk and both non-
synonymous EPHX2 polymorphisms and phase-reconstructed haplotypes were evaluated using
proportional hazards regression. Individuals carrying the K55R polymorphism variant allele
demonstrated higher apparent soluble epoxide hydrolase activity in vivo. Presence of the K55R
variant allele was significantly more common among Caucasian CHD cases when compared with
non-cases (20.8% versus 15.3%, respectively, P = 0.012), and was associated with significantly
higher risk of incident CHD (adjusted hazard rate ratio 1.45, 95% confidence interval 1.05–2.01, P
= 0.026). A significant association between the K55R variant allele and risk of CHD was not observed
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in African-Americans. The distribution of reconstructed haplotypes were significantly different in
Caucasian cases when compared with non-cases (P = 0.021). Significant differences in haplotype
distribution were not observed in African-Americans (P = 0.315). Genetic variation in EPHX2 was
significantly associated with risk of incident CHD in Caucasians, implicating EPHX2 as a potential
cardiovascular disease-susceptibility gene.
INTRODUCTION
Coronary heart disease (CHD) is a major cause of morbidity and mortality, with 1.2 million
Americans estimated to experience an acute coronary event this year (1). Endothelial
dysfunction is integrally involved in its pathogenesis (2) and is independently associated with
increased risk of acute cardiovascular events (3). Various risk factors including cigarette
smoking contribute to this process, which is typically manifested by impairment in nitric oxide
synthesis and activity (4). However, dysfunction in other endothelial pathways may also be
important.
Arachidonic acid is metabolized to epoxyeicosatrienoic acids (EETs) in endothelial cells by
various cytochromes P450 (5). The EETs possess potent vasodilatory (6,7), anti-inflammatory
(8) and fibrinolytic (9) effects and are considered one of the primary endothelial-derived
hyperpolarizing factors (6,7). The EETs are inactivated by soluble epoxide hydrolase
(EPHX2) via hydrolysis to dihydroxyeicosatrienoic acids (DHETs) (10,11). Multiple
polymorphisms in EPHX2 have been recently discovered, including variants with higher
(K55R) and lower (R287Q) epoxide hydrolase activity (12,13). An association between
EPHX2 polymorphisms and subclinical atherosclerosis has been previously reported (14);
however, associations with risk of clinical events, such as myocardial infarction, have not been
evaluated.
Our primary aim was to determine whether genetic variation in EPHX2 was associated with
risk of incident CHD events in individuals enrolled in the biethnic Atherosclerosis Risk in
Communities (ARIC) study. A secondary aim was to determine whether this risk was modified
by environmental factors known to impair endothelial function such as cigarette smoking.
RESULTS
Study population
Significant baseline differences in various risk factors were observed between incident CHD
cases and non-cases included in the cohort random sample (Table 1). Cases were significantly
older and more likely to be male, cigarette smokers, diabetic, hypertensive and have abnormal
fasting lipid panels compared with non-cases.
EPHX2 genotype
The observed race-specific allele frequencies of the 10 polymorphisms evaluated are presented
in Figure 1. The distribution of each was in Hardy–Weinberg equilibrium in both Caucasians
and African-Americans (P > 0.05). Minimal evidence of pairwise linkage disequilibrium was
observed between polymorphisms within each race; however, polymorphism 10 demonstrated
some degree of association with polymorphisms 1(D′ = 0.97, r2 = 0.28), 5(D′ = 0.96, r2 = 0.22)
and 6(D′ = 0.93, r2 = 0.28) in Caucasians and 5(D′ = 1.0, r2 = 0.20) in African-Americans.
K55R biomarker analysis
Participants with one (A/G) or two (G/G) copies of the K55R polymorphism variant allele
demonstrated significantly lower plasma 12,13-epoxyoctadecenoic acid (EpOME) to
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dihydroxy-octadecenoic acid (DHOME) ratios compared with wild-type (A/A) individuals (A/
A: 0.40 ±0.03 versus A/G: 0.31 ±0.04 versus G/G: 0.28 ±0.03; P = 0.030), indicative of higher
apparent soluble epoxide hydrolase activity in vivo. Significant differences in plasma 9,10-
EpOME:DHOME ratios were not observed (A/A: 0.34 ±0.03 versus A/G: 0.28 ±0.03 versus
G/G: 0.26 ±0.03; P = 0.155).
In the race-stratified analysis, Caucasians with one or two copies of the K55R variant allele
demonstrated significantly lower plasma 9,10-EpOME:DHOME (A/A: 0.42 ±0.04 versus A/
G: 0.28 ±0.04 versus G/G: 0.24 ±0.04; P = 0.014) and 12,13-EpOME:DHOME ratios (A/A:
0.42 ± 0.04 versus A/G: 0.31 ±0.04 versus G/G: 0.25 ±0.04; P = 0.011) compared with wild-
type individuals (Fig. 2A). Significant differences across genotype were not observed in
African-Americans for either the 9,10-EpOME:DHOME (A/A: 0.28 ±0.04 versus A/G: 0.27
±0.05 versus G/G: 0.29 ±0.05; P = 0.983) or the 12,13-EpOME:DHOME ratio (A/A: 0.38 ±0.05
versus A/G: 0.31 ±0.06 versus G/G: 0.31 ±0.06; P = 0.602) (Fig. 2B). Irrespective of genotype,
differences in 9,10-EpOME:DHOME (P = 0.395) and 12,13-EpOME:DHOME ratios (P =
0.897) were not observed across race.
Genotype association analysis
The K55R polymorphism variant allele was significantly more common among Caucasian
CHD cases compared with cohort random sample non-cases (20.8 versus 15.3%, respectively,
P = 0.012) (Table 2). This difference in genotype frequency was observed in both heterozygous
A/G (19.8 versus 14.9%) and homozygous G/G (1.0 versus 0.4%) individuals. Significant
differences were not observed in African-Americans (P = 0.344) (Table 2).
Presence of the K55R variant allele was associated with significantly higher risk of incident
CHD in Caucasians [model 3, hazard rate ratio (HRR) 1.45, 95% confidence interval (CI) 1.05–
2.01, P = 0.026, q = 0.083] (Table 3). Individuals with the heterozygous A/G (model 3, HRR
1.40, 95% CI 1.00–1.95, P = 0.047) and homozygous G/G (model 3, HRR 3.47, 95% CI 1.05–
11.5, P = 0.041) genotypes were at a significantly greater risk for developing CHD relative to
wild-type A/A individuals. This association was not modified by gender (P = 0.432 for
interaction).
No significant differences in the genotype frequency of other non-synonymous polymorphisms
were observed across case status in either race (Table 2). Moreover, the presence of the
R103C, R287Q, 402InsR or E470G polymorphism variant alleles was not significantly
associated with risk of CHD (Table 3). A significant difference in baseline diabetes diagnosis
was observed between Caucasians in the cohort random sample with (G/A or A/A) and without
(G/G) the R287Q polymorphism variant allele (1.6 versus 10.2%, respectively, P < 0.001). The
R287Q variant allele was more common in diabetic CHD cases compared with non-cases (20.1
versus 3.6%, respectively, P < 0.001); however, differences in genotype frequency were not
observed in non-diabetics (20.9 versus 20.9%, respectively, P = 0.987). Inclusion of the
R287Q*diabetes interaction term in model 3 substantially attenuated the observed trend
between the presence of the R287Q variant allele and the risk of incident CHD in Caucasians
(HRR 1.06, 95% CI 0.76–1.48, P = 0.710). Moreover, stratified analysis demonstrated no
association between the R287Q variant allele and risk of CHD in non-diabetic individuals
(model 3 minus diabetes, HRR 1.05, 95% CI 0.73–1.50, P = 0.799).
K55R Genotype and smoking
The interaction between the K55R variant allele, cigarette smoking status at baseline and risk
of CHD in Caucasians did not attain statistical significance (Table 4). When stratified by current
smoking status at baseline, the K55R variant allele was significantly more common among
Caucasian cases who smoked compared with non-cases (25.6 versus 13.6%, respectively, P =
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0.006). Significant differences were not observed in non-smokers (18.5 versus 15.8%,
respectively, P = 0.291). Caucasian smokers carrying the K55R variant allele were at higher
risk of CHD when compared with smokers without the polymorphism (model 3 minus current
smoking, HRR 2.06, 95% CI 0.99–4.27, P = 0.053). No significant association was observed
in non-smokers (model 3 minus current smoking, HRR 1.26, 95% CI 0.87–1.82, P = 0.217).
Smoking status did not modify risk associated with the K55R variant allele in African-
Americans (P = 0.709 for interaction).
Haplotype association analysis
Haplotype reconstruction including polymorphisms 1, 5, 6, 7 and 10 in Caucasians and 1, 2,
4, 5, 6 and 10 in African-Americans identified six common haplotypes in Caucasians and seven
in African-Americans, which accounted for 97.2 and 92.3% of all chromosomes, respectively.
A significant difference in the overall haplotype distribution was observed in Caucasians with
and without CHD (P = 0.021) (Table 5); however, no significant difference was observed in
African-Americans (P = 0.315) (Table 6).
In Caucasians, haplotype AGGDA (all wild-type alleles) was significantly less frequent (23.6
versus 27.6%, P = 0.034), and haplotype GGGDG (tagged by the K55R and A53415G 3′-UTR
variant alleles) was significantly more frequent (10.7 versus 7.6%, P = 0.010) in CHD cases
compared with non-cases, respectively (Table 5). Similar differences in haplotype AGGDA
and GGGDG frequency across case status were also observed using the expectation–
maximization algorithm (P = 0.010 and P = 0.052, respectively). Moreover, presence of
haplotype AGGDA was associated with significantly lower risk of CHD after covariate
adjustment (model 3, HRR 0.78, 95% CI 0.63–0.97, P = 0.028, q = 0.083), whereas the presence
of haplotype GGGDG was associated with significantly higher CHD risk (model 3, HRR 1.45,
95% CI 1.04–2.02, P = 0.030, q = 0.083) (Table 5). Significant associations were also observed
after excluding the 0.8% of individuals with a posterior haplotype probability <0.75 from the
analysis (P = 0.025 and P = 0.027, respectively).
In African-Americans, haplotype ACGGGA (all wild-type alleles) was significantly more
frequent (17.3 versus 12.2%, P = 0.026) in CHD cases compared with non-cases, respectively
(Table 6). A similar difference was also observed using the expectation–maximization
algorithm (P = 0.060). Presence of haplotype ACGGGA was associated with higher risk of
CHD after covariate adjustment (model 3, HRR 1.47, 95% CI 1.01–2.13, P = 0.042, q = 0.280)
(Table 6); however, this association was substantially weakened after exclusion of the 6.7%
of individuals with a posterior haplotype frequency <0.75 (model 3, HRR 1.37, 95% CI 0.92–
2.05, P = 0.119) and should be interpreted with caution.
DISCUSSION
Our analysis identified a statistically significant association between genetic variation in
soluble epoxide hydrolase and risk of incident CHD in Caucasians enrolled in the ARIC study,
implicating EPHX2 as a potential cardiovascular disease-susceptibility gene. Specifically, the
presence of the K55R polymorphism variant allele was associated with significantly higher
risk of developing CHD in Caucasians. Consistent with the previous in vitro findings (13), we
observed higher apparent soluble epoxide hydrolase activity in vivo in Caucasians carrying the
K55R variant allele. Variation in EPHX2 at the haplotype level was also associated with risk
of CHD in Caucasians, suggesting multiple variants within or near EPHX2 may contribute to
disease risk.
The role of endothelial dysfunction in the pathogenesis of atherosclerotic cardiovascular
disease has become increasingly appreciated. Endothelial dysfunction is typically manifested
by impairment in endothelial-dependent vasodilation (4) and is associated with increased risk
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of acute cardiovascular events (3). The vasodilatory and anti-inflammatory properties of EETs
are important mediators of this process (5,15). Recent data have demonstrated higher CHD
risk in individuals carrying the G-50T polymorphism variant allele in CYP2J2, which exhibits
lower promoter activity and EET biosynthesis (16). Soluble epoxide hydrolase rapidly
hydrolyzes EETs to DHETs and is integrally involved in regulation of their cellular levels and
vascular effects (10,11,17). EPHX2 knockout mice have significantly lower systolic blood
pressures compared with wild-type mice (18). Soluble epoxide hydrolase inhibitors
significantly reduce blood pressure in spontaneously and angiotensin II-induced hypertensive
rats (10,19,20), inhibit vascular smooth muscle cell proliferation (21), possess potent anti-
inflammatory effects (22) and represent a therapeutic strategy of potential clinical utility for
the treatment of cardiovascular disease. Moreover, we recently reported a significant
association between genetic variation in EPHX2 and risk of ischemic stroke events (23).
Resequencing efforts have identified non-synonymous polymorphisms in EPHX2 with higher
(K55R, C154Y, E470G) and lower (R287Q, 402InsR) epoxide hydrolase activity in vitro
relative to wild-type enzyme (12,13). We observed higher apparent epoxide hydrolase activity
in vivo, as measured by EpOME:DHOME ratios, in Caucasians carrying at least one K55R
variant allele; however, altered EpOME:DHOME ratios were not observed across K55R
genotype in African-American individuals. Undetectable plasma EET concentrations
precluded us from calculating EET:DHET ratios. On the basis of the role of EPHX2 in
endothelial function, we hypothesized that higher epoxide hydrolase activity would be
associated with higher risk of acute coronary events. Our findings describing a significant
association between the K55R variant allele and higher risk of incident CHD in Caucasians are
consistent with this hypothesis.
Cigarette smoking substantially impairs endothelial-dependent vasodilation in humans (4,
24), in part via inhibition of nitric oxide synthesis and activity (25), and modifies the association
between endothelial nitric oxide synthase polymorphisms, endothelial function and
cardiovascular disease risk (26,27). Perhaps, the presence of established underlying endothelial
dysfunction, as observed in cigarette smokers, may be necessary for these genetic variants to
significantly influence endothelial function and cardiovascular disease risk. Interestingly,
exposure to cigarette smoke also significantly increases vascular EPHX2 expression in mice
(28), suggesting upregulated EET hydrolysis may contribute to the deleterious effects of
cigarette smoking in the endothelium. Cigarette smoking history did not appear to influence
plasma EpOME: DHOME ratios in our biomarker study (data not shown); however, this
analysis was not designed or powered to specifically characterize such comparisons. Although
preliminary, our findings suggest that the risk of CHD associated with the K55R variant allele
may be highest in cigarette smokers. Future studies in larger populations will be required to
characterize this potential gene–environment interaction and the mechanistic contribution of
EPHX2 to the vascular effects of cigarette smoking.
Using haplotype-tagging polymorphisms identified from our previous resequencing effort, our
haplotype analysis suggests that variation along the EPHX2 gene is also an important
determinant of CHD risk in Caucasians. Distribution of reconstructed haplotypes differed
significantly across individuals with and without incident CHD, and haplotypes GGGDG and
AGGDA were associated with significantly higher and lower CHD risk, respectively. The
GGGDG haplotype was tagged by the K55R variant allele, which was associated with
significantly higher in vivo soluble epoxide hydrolase activity and CHD risk in our genotype
analysis. The R287Q and 402InsR variant alleles, which have been associated with lower
soluble epoxide hydrolase activity in vitro (12,13), were not located on either the GGGDG or
the AGGDA haplotypes. Because haplotypes are inferred, some uncertainty exists in the
haplotype assigned to each individual. This was mitigated by minimizing the number of
polymorphisms included in haplotype reconstruction (29). Moreover, similar results were
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observed using the expectation–maximization algorithm, which accounted for posterior
haplotype probabilities in the frequency comparisons across case status (30), and after
excluding individuals with posterior haplotype probabilities <0.75.
The lack of an association between CHD and the K55R polymorphism in African-Americans
could be due to lower statistical power in this subset. However, we also observed no apparent
influence of K55R genotype on in vivo soluble epoxide hydrolase activity in African-
Americans, whereas significant genotype-dependent differences were observed in Caucasians.
Perhaps, certain genetic and/or environmental factors not accounted for in our analysis could
have contributed to these racial differences in soluble epoxide hydrolase activity and CHD
risk. Future studies evaluating the vascular effects of EPHX2 in Caucasians and African-
Americans appear warranted, particularly because racial differences in endothelial-targeted
therapies have been reported in other cardiovascular disease populations (31).
An association between the R287Q variant allele and increased coronary artery calcification,
a non-invasive measure of atherosclerotic burden, was recently reported in African-Americans
(14). The mechanism underlying this association remains unclear because this variant has
demonstrated lower soluble epoxide hydrolase activity in vitro (12,13). We did not observe a
significant association between this variant and risk of CHD clinical events in our analysis.
Although a non-significant trend toward higher risk was observed in Caucasians (model 3
only), this relationship was modified by baseline diabetes diagnosis. No association with CHD
risk was observed in non-diabetics, whereas the apparent trend in diabetics was driven by a
lower R287Q minor allele frequency in diabetic non-cases (0.017) than expected based on
previously reported frequencies (approximately 0.10) (13,14).
Although our study evaluated rigorously ascertained incident events, we are unable to elucidate
mechanisms underlying the observed associations between genetic variation in EPHX2 and
CHD risk. Moreover, we cannot rule out that the K55R polymorphism is simply a marker in
linkage disequilibrium with the true causative locus. However, our analysis accounted for
multiple EPHX2 polymorphisms and also demonstrated significant associations between
haplotype and CHD risk in Caucasians. Although we specifically selected polymorphisms in
this candidate gene with known functional relevance in vitro and/or haplotype tagging
properties and utilized a hypothesis-driven approach in our analysis, we acknowledge that it
may be difficult to gauge the statistical significance of these findings considering the number
of comparisons completed. Moreover, we recognize the undesirable consequences of reporting
false-positive findings. However, concerns surrounding false-negative findings (i.e. missing
true associations) are at least as important. In order to minimize the impact of the multiple tests
completed in our analysis, we assessed the false discovery rate (FDR) across all completed
tests in our genotype and haplotype association analysis, recognizing that such an approach is
likely an over-correction because certain genotype and haplotype associations are not
completely independent and the same independent variables were evaluated by each of the
three models utilized in our analysis. Because all q-values in Caucasians were conservatively
estimated to be ≤0.083, we have a high level of confidence in our reported findings, although
validation in an independent population is necessary.
In conclusion, our findings suggest that genetic variation in EPHX2, particularly the presence
of the K55R polymorphism variant allele, may be an important risk factor for the development
of CHD clinical events in Caucasians. Association studies in different populations will
undoubtedly be required to validate our findings, in addition to molecular and physiological
studies evaluating the mechanistic relationship between soluble epoxide hydrolase, endothelial
function and cardiovascular disease risk.
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Participants were selected from the ARIC study, a longitudinal, population-based cohort study
of 15 792 men and women aged 45–64 from four US communities (Forsyth County, NC;
Jackson, MS; Minneapolis, MN and Washington County, MD) enrolled between 1987 and
1989 (32). Since enrollment, participants have been followed prospectively via annual phone
interviews, clinical examinations approximately every 3 years through 1998 and ongoing
abstraction of hospital and death certificate records. The study protocol was approved by the
Institutional Review Board of each center, and consent was obtained from each participant.
Ascertainment of incident CHD cases
All incident cases that occurred between baseline and December 31, 1998 were evaluated
(median follow-up 9.1 years), excluding subjects with a history of CHD or stroke at baseline.
Incident CHD (n = 1085) was defined as (i) definite or probable myocardial infarction (n =
520), (ii) electrocardiographic evidence of silent myocardial infarction (n = 112), (iii) definite
CHD death (n = 110) or (iv) coronary revascularization procedure (n = 343).
The ascertainment of cases and criteria for classification have been previously described
(33). All potential events were systematically reviewed and adjudicated by the ARIC Morbidity
and Mortality Classification Committee (32,33). Hospitalized myocardial infarction was
classified as definite or probable based on chest pain symptoms, cardiac enzyme levels and
electrocardiographic changes. Definite CHD death was classified based on chest pain
symptoms, underlying cause of death, hospitalization records and medical history. Coronary
revascularization procedures included coronary artery bypass grafting and percutaneous
coronary interventions.
Baseline measurements
Detailed demographic, clinical and biochemical data were obtained from each subject at
baseline. Race was self-reported. Prevalent CHD and stroke were defined as history of a
physician-diagnosed event. Hypertension was defined as systolic blood pressure ≥140 mmHg,
diastolic blood pressure ≥90 mmHg or current antihypertensive medication use. Diabetes was
defined as fasting blood glucose ≥7.0 mmol/l, non-fasting blood glucose ≥11.1 mmol/l,
physician diagnosis or pharmacological treatment. Detailed information on cigarette smoking
was obtained through an interview-administered questionnaire.
Cohort random sample
A random sample of all ARIC participants without history of CHD or stroke at baseline was
assembled to serve as the reference group for the case–cohort comparisons (n = 1065, 85 of
which are also incident CHD cases). Sampling of the cohort was stratified on age (<55 or ≥55
years), gender and race (Caucasian or African-American). Sampling proportions varied across
each stratum. The term non-case refers to individuals within the cohort random sample who
did not develop incident CHD during follow-up (n = 980).
Genotyping
Genomic DNA from all incident CHD cases and the cohort random sample was genotyped for
10 polymorphisms in coding and non-coding regions of EPHX2 (Fig. 1), using multiplex
matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry
(Sequenom Inc., San Diego, CA, USA) (34) or Taqman® (Applied Biosystems, Foster City,
CA, USA) (35) methods, as described (see Supplementary Material). Blind replicates were
included for quality control. Missing genotypes were present in <5% of individuals. These
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polymorphisms were identified from our resequencing effort as part of the NIEHS
Environmental Genome Single Nucleotide Polymorphism program (http://dir-
apps.niehs.nih.gov/egsnp/home.htm) (13) and specifically selected based on their known
functional relevance in vitro (12,13) and/or haplotype-tagging properties. Briefly, pairwise
linkage disequilibrium statistics were calculated and haplotypes were reconstructed separately
in European/Caucasians (n = 24) and Africans (n = 24) using all polymorphisms along
EPHX2 identified by resequencing (Haploview 3.2) (13,30). Polymorphisms tagging
haplotypes with >5% frequency in either population were selected for genotyping (36).
Biomarker analysis
Plasma from the most recent clinic visit was obtained from 56 participants selected based on
their K55R genotype [A/A (n = 19), A/G (n = 19), G/G (n = 18)] and matched for age, gender
and race. Plasma samples were extracted and EpOME and DHOME concentrations were
quantified using a validated HPLC/MS/MS method, as described (37). Previous studies in our
lab with Ephx2 knockout mice suggest that plasma EpOME:DHOME ratios are sensitive and
specific biomarkers of soluble epoxide hydrolase activity, with lower EpOME:DHOME values
indicative of higher apparent soluble epoxide hydrolase activity (J.M. Seubert and D.C. Zeldin,
unpublished data).
Data analysis
All incident CHD cases and individuals from the cohort random sample were included in our
analysis (n = 2065). Inverse sampling fractions from each stratum were used as weights in
variance estimation of adjusted covariate means and proportions by linear and logistic
regression, respectively, in non-cases included in the cohort random sample. HRRs and 95%
CIs for the development of incident CHD in relation to EPHX2 genotype were calculated by
weighted proportional hazards regression, using Barlow’s method to account for the stratified
random sampling and case–cohort design (38). Model 1 was unadjusted and included only
genotype. Model 2 included age, gender and study center as covariates. Model 3 also included
current smoking status, diabetes, hypertension, high density lipoprotein cholesterol, total
cholesterol and body mass index. Assuming an autosomal dominant mode of inheritance,
individuals with one or two variant alleles were combined for comparison with wild-type
individuals. All analyses were completed separately in Caucasians and African-Americans.
Assuming a case–control design and type I error α = 0.05, we had ~99 and 80% power to detect
an odds ratio of 2.0, and 70 and 30% power to detect an OR of 1.5 in Caucasians and African-
Americans, respectively, for polymorphisms with a 10% variant genotype frequency.
Gene–environment interaction testing was completed on a multiplicative scale between
genotype and baseline current smoking status (yes/no) using a Wald chi-square test for
significance of the estimated β-coefficient for the interaction term (39). Because interaction
hypothesis testing on a multiplicative scale is underpowered, the critical value for statistical
significance was set to α = 0.15, two-sided (40). Stratified weighted proportional hazards
regression was also completed according to baseline current smoking status using the model
3 covariate adjustment strategy (minus current smoking status) to further explore potential
interactions.
Cohort random sample allele frequencies were evaluated for deviation from Hardy–Weinberg
equilibrium, and pairwise linkage disequilibrium statistics were calculated (Haploview 3.2)
(30). Haplotypes and their frequencies were estimated using the phase reconstruction method
(PHASE 2.1), which assigned the most probable haplotype pair to each individual (41,42).
Only polymorphisms with >5% frequency were considered for haplotype reconstruction, which
included polymorphisms 1, 5, 6, 7 and 10 in Caucasians and 1, 2, 4, 5, 6 and 10 in African-
Americans (Fig. 1). Haplotype frequencies were compared across case status by chi-square,
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and only haplotypes with >5% frequency were considered. Frequency comparisons were
repeated using the expectation–maximization algorithm (Haploview 3.2) (30), which
accounted for the uncertainty in haplotype reconstruction by weight-adjusting each inferred
haplotype according to its estimated posterior haplotype probability. Associations between
haplotype (0, 1, 2) and risk of incident CHD were also evaluated by modeling each haplotype
relative to all other haplotypes using Barlow’s method (38). The association analysis was
repeated after excluding individuals with posterior haplotype probabilities <0.75.
To minimize the impact of the multiple statistical tests conducted in our analysis, we estimated
the FDR q-value of our findings, which is defined as the proportion of statistical tests deemed
significant that are actually false-positives (QVALUE) (43). In order to calculate conservative
q-value estimates, we considered statistical tests from the models’ 1, 2 and 3 association
analysis of each non-synonymous polymorphism (Table 3) and reconstructed haplotype
(Tables 5 and 6) as independent even though each model assessed the same independent
variable.
Plasma EpOME:DHOME ratios were compared across K55R genotype by analysis of variance,
and post hoc comparisons between genotypes were completed using the Tukey–Kramer test.
All data are presented as mean ±standard error of the mean.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Nucleotide positions of the 10 polymorphisms evaluated are given relative to the EPHX2 cDNA
start site (GenBank accession no. NT_022666). Activity is reported as higher (↑), lower (↓),
unchanged (↔) or unknown (?) relative to wild-type enzyme based on previous in vitro studies
(12,13). Minor allele frequencies are presented separately by race and P-values for their
comparison are reported.
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Mean (± standard error of the mean) calculated plasma EpOME:DHOME ratios are presented
according to K55R genotype in Caucasians (A) and African-Americans (B). 9,10-
EpOME:DHOME (black bars, *P < 0.05 versus A/A), and 12,13-EpOME:DHOME (white
bars, ^P < 0.05 versus A/A) ratios are presented.
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Table 1
Baseline characteristics by incident CHD case status
Characteristicsa CRS non-cases Incident CHD cases P-value
n 980 1085
Gender (% male) 41.2% 67.4% <0.001
Race (% Caucasian) 72.9% 76.6% 0.004
Age (years) 53.8 ±0.10 55.8 ±0.17 <0.001
Current smoker (% yes) 24.8% 36.1% <0.001
Pack-years >20 (% yes) 28.9% 48.6% <0.001
Diabetes (%) 11.0% 25.1% <0.001
Hypertension (%) 29.6% 49.4% <0.001
SBP (mmHg) 120.3 ±0.58 128.3 ±0.63 <0.001
DBP (mmHg) 73.3 ±0.37 76.2 ±0.38 <0.001
BMI (kg/m2) 27.7 ±0.20 28.3 ±0.15 0.017
HDL cholesterol (mmol/l) 1.38 ±0.02 1.12 ±0.01 <0.001
LDL cholesterol (mmol/l) 3.46 ±0.03 3.92 ±0.03 <0.001
Total cholesterol (mmol/l) 5.48 ±0.03 5.86 ±0.03 <0.001
Triglycerides (mmol/l) 1.41 ±0.03 1.87 ±0.04 <0.001
Data are presented as mean ±standard error of the mean or proportion. CRS, cohort random sample; Pack-years, [(cigarettes smoked per day/20) × (years
smoked)] and are reported as proportion of individuals with a >20 pack-year history at baseline; SBP, systolic blood pressure; DBP, diastolic blood
pressure; BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein.
a
Characteristics are weighted according to the sampling fraction.
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Table 2
Non-synonymous EPHX2 polymorphism frequency by CHD case status




Non-cases CHD cases P-
value
K55R K55R
A/A 461 (84.7%) 608 (79.2%) A/A 179 (57.6%) 138 (61.9%)
A/G + G/G 87 (15.3%) 160 (20.8%) 0.012 A/G + G/G 127 (42.4%) 85 (38.1%) 0.344
A allele 92.1% 89.1% A allele 76.4% 78.9%
G allele 7.8% 10.9% 0.009 G allele 23.6% 21.1% 0.351
R103C R103C
C/C 565 (98.7%) 773 (100%) C/C 247 (80.7%) 180 (81.1%)
C/T + T/T 8 (1.3%) 0 (0%) N/A C/T + T/T 60 (19.3%) 42 (18.9%) 0.915
C allele 99.4% 100% C allele 90.0% 90.1%
T allele 0.6% 0% N/A T allele 10.0% 9.9% 0.968
R287Q R287Q
G/G 496 (80.6%) 616 (79.2%) G/G 258 (82.9%) 190 (86.0%)
G/A + A/A 118 (19.4%) 162 (20.8%) 0.525 G/A + A/A 49 (17.1%) 31 (14.0%) 0.361
G allele 89.9% 89.0% G allele 91.3% 92.3%
A allele 10.1% 11.0% 0.485 A allele 8.7% 7.7% 0.569
402InsRb 402InsRb
D/D 527 (87.6%) 687 (88.1%) D/D 301 (99.2%) 219 (98.2%)
D/I + I/I 76 (12.4%) 93 (11.9%) 0.792 D/I + I/I 3 (0.8%) 4 (1.8%) N/A
D allele 93.5% 93.8% D allele 99.6% 99.1%
I allele 6.5% 6.2% 0.694 I allele 0.4% 0.9% N/A
E470G E470G
A/A 557 (100%) 774 (100%) A/A 300 (97.8%) 222 (97.8%)
A/G + G/G 0 (0%) 0 (0%) N/A A/G + G/G 5 (2.2%) 5 (2.2%) 0.974
A allele 100% 100% A allele 98.9% 98.9%
G allele 0% 0% N/A G allele 1.1% 1.1% 0.975
a
Data presented as absolute (percent) genotype frequency and allele frequency. Frequencies are weighted according to the sampling fraction. Data for
polymorphisms 3 (C154Y ) and 8 (V422A) are not included due to minor allele frequencies ≤0.1% in both races.
b
For 402InsR (polymorphism 7), the deletion allele is designated by D and the CGT insertion allele by I.
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Table 3
HRR between non-synonymous polymorphisms in EPHX2 and risk of incident CHD
Polymorphism Caucasian HRR 95% CI P-value African-
American HRR
95% CI P-value
K55R A/G + G/G versus A/A A/G + G/G versus A/A
Model 1a 1.43 1.07–1.90 0.015 0.87 0.60–1.27 0.474
Model 2b 1.36 1.01–1.83 0.045 0.87 0.61–1.25 0.466
Model 3c 1.45 1.05–2.01 0.026 0.76 0.50–1.16 0.208
R103C C/T + T/T versus C/C
Model 1a N/A 0.87 0.55–1.35 0.528
Model 2b N/A 0.95 0.61–1.47 0.801
Model 3c N/A 0.94 0.58–1.51 0.787
R287Q G/A + A/A versus G/G G/A + A/A versus G/G
Model 1a 1.03 0.78–1.36 0.827 0.87 0.52–1.44 0.560
Model 2b 1.17 0.88–1.54 0.284 0.90 0.55–1.49 0.685
Model 3c 1.34 0.96–1.87 0.082 1.13 0.64–2.01 0.676
402InsRd D/I + I/I versus D/D D/I + I/I versus D/D
Model 1a 0.96 0.69–1.34 0.819 1.64 0.47–5.86 0.603
Model 2b 1.00 0.72–1.39 0.998 1.40 0.39–4.97 0.603
Model 3c 1.00 0.70–1.45 0.990 1.26 0.43–3.71 0.675
E470G A/G + G/G versus A/A
Model 1a N/A 1.33 0.35–5.02 0.679
Model 2b N/A 1.71 0.50–5.85 0.396
Model 3c N/A 1.87 0.52–6.75 0.338
N/A, modeling not completed because SNP frequency = 0% in incident CHD case and/or non-case group. Data for polymorphisms 3 (C154Y ) and 8




Adjusted for age, gender and study center.
c
Adjusted for age, gender, study center, current smoker, diabetes, hypertension, HDL cholesterol, total cholesterol and body mass index.
d
For 402InsR (polymorphism 7), the deletion allele is designated by D and the CGT insertion allele by I.
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Table 4
K55R by smoking interaction and risk of incident CHD in Caucasians
Susceptibility genotype (K55R)
Smoking exposure A/A A/G + G/G
Non-current smokers
 Model 2a 1 (referent) 1.16 (0.81–1.64)
 Model 3b 1 (referent) 1.26 (0.87–1.80)
Current smokers
 Model 2a 1.57 (1.17–2.11) 2.84 (1.62–4.99)
 Model 3b 1.57 (1.14–2.16) 2.93 (1.54–5.55)
Data are presented as HRR (95% CI).
a
Adjusted for age, gender and study center (interaction term: HRR 1.57, 95% CI 0.78–3.13, P = 0.205).
b
Adjusted for age, gender, study center, diabetes, hypertension, HDL cholesterol, total cholesterol and body mass index (interaction term: HRR 1.49, 95%
CI 0.69–3.18, P = 0.308).
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Table 5
EPHX2 haplotypes and risk of incident CHD in Caucasians
Distribution analysis Association analysis
Haplotype,abc Non-cases CHD cases P-valued HRRe 95% CI P-value
n = 510 n = 748
AAGDA 41.5% 43.8% 1.02 0.84–1.24 0.842
AGGDA 27.6% 23.6% 0.78 0.63–0.97 0.026
AGADG 9.9% 10.7% 1.39 0.97–1.99 0.073
GGGDG 7.6% 10.7% 1.45 1.04–2.02 0.030
AGGIA 6.5% 6.2% 0.98 0.67–1.42 0.908
AGGDG 6.9% 5.1% 0.021 0.84 0.58–1.22 0.367
a
Bold nucleotides represent haplotype tagging polymorphisms.
b
Estimated copy frequency of each haplotype weighted according to the sampling fraction.
c
Haplotype includes polymorphisms 1, 5, 6, 7 and 10, respectively. For polymorphism 7 (402InsR), the deletion allele is designated by D and the CGT
insertion allele by I.
d
Chi-square P-value for the overall distribution of haplotypes by CHD case status.
e
Adjusted for age, gender, study center, current smoker, diabetes, hypertension, HDL cholesterol, total cholesterol and body mass index.
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Table 6
EPHX2 haplotypes and risk of incident CHD in African-Americans
Distribution analysis Association analysis
Haplotype,abc Non-cases CHD cases P-valued HRRe 95% CI P-valuee
n = 305 n = 220
ACGGGG 24.3% 21.8% 0.84 0.57–1.24 0.377
GCGGGG 22.6% 20.9% 0.85 0.59–1.23 0.396
ACCGGG 15.1% 15.6% 1.09 0.70–1.68 0.703
ACGGGA 12.2% 17.3% 1.47 1.01–2.13 0.042
ACGAGA 9.8% 10.1% 1.08 0.68–1.70 0.750
ACGGAG 8.8% 6.2% 0.89 0.48–1.67 0.718
ATGGGA 7.2% 8.2% 0.315 1.32 0.78–2.23 0.304
a
Bold nucleotides represent haplotype tagging polymorphisms.
b
Estimated copy frequency of each haplotype weighted according to the sampling fraction.
c
Haplotype includes polymorphisms 1, 2, 4, 5, 6 and 10, respectively.
d
Chi-square P-value for the overall distribution of haplotypes by CHD case status.
e
Adjusted for age, gender, study center, current smoker, diabetes, hypertension, HDL cholesterol, total cholesterol and body mass index.
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